New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

January 2012

Palatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits

Press Releases / By

CRANBURY, N.J., Jan. 17, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today it has received net proceeds of approximately $1.1 million of non-dilutive funding through the New Jersey Economic Development Authority’s tax credit transfer program.  Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations. …

Palatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits Read More »

Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets’ Eighth Annual Equity Conference

Press Releases / By

CRANBURY, N.J., Jan. 16, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer will present at BOCEMb, Noble Financial Capital Markets’ Eighth Annual Equity …

Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets’ Eighth Annual Equity Conference Read More »

Scroll to Top